Published in Cell Cycle on May 26, 2009
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival. BMC Cancer (2011) 0.94
Spotlight on differentially expressed genes in urinary bladder cancer. PLoS One (2011) 0.94
Ras and Raf pathways in epidermis development and carcinogenesis. Br J Cancer (2010) 0.93
Altered metabolic pathways in clear cell renal cell carcinoma: A meta-analysis and validation study focused on the deregulated genes and their associated networks. Oncoscience (2014) 0.92
Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget (2011) 0.89
RKIP inhibition in cervical cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapy. PLoS One (2013) 0.89
RAF-kinase inhibitor protein (RKIP) downregulation in esophageal cancer and its metastases. Clin Exp Metastasis (2012) 0.83
Role of Raf-kinase inhibitor protein in colorectal cancer and its regulation by hydroxycamptothecine. J Biomed Sci (2015) 0.77
Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res (2003) 2.01
MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle (2011) 1.90
Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. Eur J Hum Genet (2002) 1.73
Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol (2004) 1.73
Molecular diagnostic tools in mycobacteriology. J Microbiol Methods (2008) 1.66
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res (2010) 1.59
Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res (2012) 1.57
Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents (2010) 1.55
Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res (2004) 1.46
The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol (2009) 1.46
Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma. Leuk Lymphoma (2014) 1.44
Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res (2006) 1.43
Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res (2014) 1.39
Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res (2007) 1.39
A 3,000-year-old child's toy. Eur J Pediatr (2012) 1.38
The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol (2012) 1.38
Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol (2005) 1.37
Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J Immunol (2004) 1.35
Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol (2011) 1.34
Pathogenetic mechanisms and treatment options for ophthalmic pterygium: trends and perspectives (Review). Int J Mol Med (2009) 1.31
Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer (2009) 1.31
Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol (2009) 1.31
Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene (2004) 1.30
Interleukin 8 and cardiovascular disease. Cardiovasc Res (2009) 1.28
NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol (2008) 1.25
Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res (2004) 1.25
Uterine cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol (2009) 1.24
Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res (2007) 1.23
Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol (2007) 1.21
IL-1 cytokines in cardiovascular disease: diagnostic, prognostic and therapeutic implications. Cardiovasc Hematol Agents Med Chem (2008) 1.16
Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. Int J Oncol (2007) 1.15
Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol (2006) 1.15
Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb Res (2006) 1.15
Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res (2007) 1.15
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer (2010) 1.14
Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol (2003) 1.14
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol (2008) 1.13
Understanding tobacco smoke carcinogen NNK and lung tumorigenesis. Int J Oncol (2006) 1.13
Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther (2004) 1.12
Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J Immunol (2007) 1.12
Nitric oxide donors: novel cancer therapeutics (review). Int J Oncol (2008) 1.12
Influence of the apolipoprotein E epsilon4 allele on human embryonic development. Neurosci Lett (2002) 1.10
Human papilloma virus (HPV) infection in children and adolescents. Eur J Pediatr (2008) 1.09
Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther (2003) 1.08
Prevalence of human herpes virus types 1-7 in the semen of men attending an infertility clinic and correlation with semen parameters. Fertil Steril (2008) 1.08
Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene (2005) 1.07
Yin yang 1 expression in human tumors. Cell Cycle (2010) 1.07
Identification of common differentially expressed genes in urinary bladder cancer. PLoS One (2011) 1.06
From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review). Int J Oncol (2013) 1.06
Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clin Immunol (2006) 1.06
Vaccination against human papilloma virus (HPV): epidemiological evidence of HPV in non-genital cancers. Pathol Oncol Res (2010) 1.06
Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene (2004) 1.06
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate (2002) 1.06
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol (2012) 1.06
Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood (2006) 1.05
Viral involvement in the pathogenesis and clinical features of ophthalmic pterygium (Review). Int J Mol Med (2013) 1.04
Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP. Cell Cycle (2010) 1.04
p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett (2002) 1.03
Female genital tuberculosis: a review. Scand J Infect Dis (2011) 1.03
T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis. Pediatr Infect Dis J (2006) 1.02
Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Res (2009) 1.01
Deregulation of RNA polymerase III transcription in cervical epithelium in response to high-risk human papillomavirus. Oncogene (2005) 1.00
Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther (2007) 1.00
Recruitment of human cytomegalovirus immediate-early 2 protein onto parental viral genomes in association with ND10 in live-infected cells. J Virol (2007) 0.99
K-ras mutation, HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinoma. Pathol Oncol Res (2008) 0.97
Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF-κB/Snail/YY1/RKIP circuitry. Nitric Oxide (2010) 0.97
Growth factor expression in ophthalmic pterygia and normal conjunctiva. Int J Mol Med (2010) 0.97
Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res (2009) 0.97
TRAF6 activation in multiple myeloma: a potential therapeutic target. Clin Lymphoma Myeloma Leuk (2012) 0.96
DNA methylation in the human placenta and fetal growth (review). Mol Med Rep (2012) 0.96
Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases. Nitric Oxide (2008) 0.96
Genetic diversity of CX3CR1 gene and coronary artery disease: new insights through a meta-analysis. Atherosclerosis (2009) 0.96
Loss of imprinting and aberrant methylation of IGF2 in placentas from pregnancies complicated with fetal growth restriction. Int J Mol Med (2011) 0.96
The NO TRAIL to YES TRAIL in cancer therapy (review). Int J Oncol (2007) 0.96
VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett (2005) 0.96
Retracted Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res (2010) 0.95
Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol Ther (2010) 0.95
Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol (2006) 0.95
CYP1A1, CYP19, and GSTM1 polymorphisms increase the risk of endometriosis. Fertil Steril (2003) 0.95
'Genetic profiling' and ovarian cancer therapy (review). Mol Med Rep (2011) 0.95
Proinflammatory circulating molecules in peripheral arterial disease. Int J Mol Med (2007) 0.95
Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des (2009) 0.94
Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival. BMC Cancer (2011) 0.94